Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
复制标题
DOI：
10.1038/bjc.2011.402
复制
发表时间：
2011-10-25
影响因子：
8.8
通讯作者：
Panasci, L. C.
中科院分区：
文献类型：
--
作者：
Sahebjam, S.;Aloyz, R.;Panasci, L. C.
背景：Ki 67 表达的免疫组织学评估比 Oncotype Dx 便宜，Oncotype Dx 目前用于识别淋巴结阴性乳腺癌患者，这些患者将从辅助化疗中受益。方法：在 53 例 TI-2 N0 M0（雌激素受体阳性，HER2/neu 阴性）乳腺癌病例中检查了免疫组织学测量的 Ki 67 与 Oncotype DX 复发评分 (RS) 的关系。 Ki 67 值与 Oncotype Dx RS 之间具有很强的线性相关性。低Ki 67 组（Ki 67 = 25%）的所有患者均具有高或中度风险的Oncotype RS。结论：Ki 67 增殖值是Oncotype Dx 评分的主要决定因素，但不是唯一决定因素。英国癌症杂志 (2011) 105, 1342-1345。 doi:10.1038/bjc.2011.402 www.bjcancer.com 2011 年 10 月 4 日在线发布 (C) 2011 英国癌症研究中心
BACKGROUND: Immunohistological assessment of Ki 67 expression is less expensive than Oncotype Dx, which is currently used to identify patients with lymph node-negative breast cancer, who will benefit from adjuvant chemotherapy.METHODS: The relationship of immunohistologically measured Ki 67 to Oncotype DX recurrence score (RS) was examined in 53 cases of TI-2 N0 M0 (oestrogen receptor-positive, HER2/neu negative) breast cancer.RESULTS: There was a strong linear correlation between Ki 67 value and the Oncotype Dx RS. All patients in the low Ki 67 group (Ki 67 of = 25%) had oncotype RSs of high or intermediate risk.CONCLUSION: Ki 67 proliferation value is a major, but not the sole determinant of Oncotype Dx score. British Journal of Cancer (2011) 105, 1342-1345. doi:10.1038/bjc.2011.402 www.bjcancer.com Published online 4 October 2011 (C) 2011 Cancer Research UK